Journal of Neurology

, Volume 253, Supplement 1, pp i16–i20 | Cite as

Botulinum toxin in multiple sclerosis

Abstract

Local administration of botulinum toxin (BoTx) inhibits presynaptic acetylcholine release. All cholinergically innervated muscles and glands can be paralyzed accordingly. Studies on the application of BoTx in multiple sclerosis have shown good results for focal spasticity, in particular, of the extremities. The first promising data were published on bladder disorders, especially with regard to detrusor sphincter dyssynergia and detrusor hyperreflexia. Hyperhidrosis, hypersalivation and proctologic symptoms might be other areas of application. Approval, however, has been greatly restricted which limits the therapeutic range of use.

Key words

multiple sclerosis botulinum toxin therapy spasticity bladder disturbances 

References

  1. 1.
    Bakheit AM, Thilmann AF, Ward AB, Poewe W, Wissel J, Müller J, Benecke R, Collin C, Müller F, Ward CD, Neumann C (2000) A randomized, double-blind, placebo-controlled, dose-ranging study to compare the efficacy and safety of three doses of botulinum toxin type A (Dysport) with placebo in upper limb spasticity after stroke. Stroke 31:2402–2406PubMedGoogle Scholar
  2. 2.
    Beard S, Hunn A, Wight J (2003) Treatments for spasticity and pain in multiple sclerosis: a systemic review. Health Techn Asses 7:1–111Google Scholar
  3. 3.
    Borg-Stein J, Pine ZM, Miller JR, Brin MF (1993) Botulinum toxin for the treatment of spasticity in multiple sclerosis. Am J Phys Med Rehabil 72:364–368PubMedGoogle Scholar
  4. 4.
    Brashear A, Gordon MF, Elovic E, Kassicieh VD, Marciniak C, Do M, Lee CH, Jenkins S, Turkel C (2002) Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med 347:395–400CrossRefPubMedGoogle Scholar
  5. 5.
    Cava TJ (1995) Botulinum toxin management of spasticity in upper motor neuron lesion. Eur J Neurol 2(Suppl 3):57–60Google Scholar
  6. 6.
    Chen JJ, Swope DM (2003) Essential tremor: diagnosis and treatment. Pharmacotherapy 23:1105–1122PubMedGoogle Scholar
  7. 7.
    Cheshire WP, Abashian SW, Mann JD (2000) Botulinum toxin in the treatment of myofascial pain syndrome. Pain 59:65–69Google Scholar
  8. 8.
    Daelen B, Thorwirth V, Koch A (1997) Treatment of recurrent dislocation of the temporomandibular joint with type A Botulinum toxin. Int J Maxillofac Surg 26:458–460Google Scholar
  9. 9.
    Drobik C, Laskawi R (1995) Frey’s syndrome: treatment with botulinum toxin. Acta Otolaryngol 115:459–461PubMedGoogle Scholar
  10. 10.
    Dykstra DD, Sida AA, Scott AB, Pagel JM, Goldish GD (1988) Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol 139:912–922Google Scholar
  11. 11.
    Ellies M, Laskawi R, Rohrbach-Volland S, Arglebe C (2003) Up-to-date report of botulinum toxin therapy in patients with drooling caused by different etiologies. J Oral Maxillofac Surg 61:454–457CrossRefPubMedGoogle Scholar
  12. 12.
    Finsterer J, Fuchs I, Mamoli B (1997) Automatic EMG-guided botulinum toxin treatment of spasticity. Clin Neuropharmacol 20:195–203PubMedGoogle Scholar
  13. 13.
    Foster L, Clapp L, Erickson M, Jabbari B (2001) Botulinum toxin A and chronic low back pain: a randomized, double-blind study. Neurology 56:1290–1293PubMedGoogle Scholar
  14. 14.
    Grazko M, Polo KB, Jabbari B (1995) Botulinum toxin A for spasticity, muscle spasms and rigidity. Neurology 45:12–17Google Scholar
  15. 15.
    Grosse J, Kramer G, Stohrer M (2005) Success of repeat detrusor injections of botulinum A toxin in patients with severe neurogenic detrusor overactivity and incontinence. Eur Urol 47:653–659CrossRefPubMedGoogle Scholar
  16. 16.
    Gupta VK (2005) Botulinum toxin type A therapy for chronic tension-type headache: fact versus fiction. Pain 116:166–167CrossRefPubMedGoogle Scholar
  17. 17.
    Hyman N, Barnes M, Bhakta B, Cozens A, Bakheit M, Kreczy-Kleedorfer B, Poewe W, Wissel J, Bain P, Glickman S, Sayer A, Richardson A, Dott C (2000) Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double-blind, placebo controlled, dose ranging study. J Neurol Neurosurg Psychiatry 68:707–712CrossRefPubMedGoogle Scholar
  18. 18.
    Jost WH (2002) Ten years experience with botulinum toxin in anal fissure. Int J Colorect Dis 17:298–302CrossRefGoogle Scholar
  19. 19.
    Jost WH Naumann M (2004) Botulinum toxin in neuro-urological disorders. Mov Disord 19:S142–S145CrossRefPubMedGoogle Scholar
  20. 20.
    Jost WH (2005) Botulinum toxin in expanded use. Eur J Neurol 2005; EpubGoogle Scholar
  21. 21.
    Naumann M, Jankovic J (2004) Safety of botulinum toxin type A: a systematic review and meta-analysis. Curr Med Res Opin 20:981–990CrossRefPubMedGoogle Scholar
  22. 22.
    Naumann M, Jost W (2004) Botulinum toxin treatment of secretory disorders. Mov Disord 19(Suppl 8):S137–S141CrossRefPubMedGoogle Scholar
  23. 23.
    O’Brien CF (2002) Treatment of spasticity with botulinum toxin. Clin J Pain 18(Suppl 6):S182–S190PubMedGoogle Scholar
  24. 24.
    Padberg M, de Bruijn SF, de Haan RJ, Tavy DL (2004) Treatment of chronic tension-type headache with botulinum-toxin: a double blind, placebo controlled trial. Cephalalgia 24:675–680CrossRefPubMedGoogle Scholar
  25. 25.
    Pal PK, Samii A, Schulzer M, Mak E, Tsui JK (2000) Head tremor in cervical dystonia. Can J Neurol Sci 27:137–142PubMedGoogle Scholar
  26. 26.
    Pöllmann W, Feneberg W, Steinbrecher A, Haupts MR, Henze T (2005) Therapy of pain syndromes in multiple sclerosis—an overview with evidence-based recommendations. Fortschr Neurol Psychiat 73:268–285PubMedGoogle Scholar
  27. 27.
    Reichel G (2001) Botulinum toxin for the treatment of spasticity in adults. J Neurol 248(Suppl 1):S25–S27Google Scholar
  28. 28.
    Reitz A, Stöhrer M, Kramer G, Del Popolo G, Chartier-Kastler E, Pannek J, Burgdorfer H, Gocking K, Madersbacher H, Schumacher S, Richter R, von Tobel J, Schurch B (2004) European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overacticity. Eur Urol 45:510–515PubMedGoogle Scholar
  29. 29.
    Rontal E, Rontal M, Wald J, Rontal D (1999) Botulinum toxin injection in the treatment of vocal fold paralysis associated with multiple sclerosis: a case report. J Voice 13:274–279CrossRefPubMedGoogle Scholar
  30. 30.
    Schnider P, Binder M, Auff E, Kittler H, Berger T, Wolff K (1997) Double-blind trial of botulinum toxin for the treatment of focal hyperhidrosis of the palms. Br J Neurol 136:548–552Google Scholar
  31. 31.
    Schurch B, De Sèze M, Denys P, Chartier-Kastler E, Haab F, Everaert K, Plante P, Perrouin-Verbe B, Kumar C, Fraczek S, Brin MF (2005) Botulinum toxin type A is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol 174:196–200CrossRefPubMedGoogle Scholar
  32. 32.
    Sedano MJ, Trejo JM, Macarron JL, Polo JM, Berciano J, Calleja J (2000) Continuos facial myokymia in multiple sclerosis: treatment with botulinum toxin. Eur Neurol 43:137–140CrossRefPubMedGoogle Scholar
  33. 33.
    Smith CP, Nishiguchi J, O’Leary M, Yoshimura N, Chancellor MB (2005) Single-institution experience in 110 patients with botulinum toxin A injection into bladder or urethra. Urology 65:37–41PubMedGoogle Scholar
  34. 34.
    Snow BJ, Tsui J, Bhatt M, Varelas M, Hashimoto SA, Calne DB (1990) Treatment of spasticity with botulinum toxin: a double-blind study. Ann Neurol 28:512–515CrossRefPubMedGoogle Scholar
  35. 35.
    Svetel M, Sternie N, Filipovic S, Kostic V (1997) Spasmodic torticollis associated with multiple sclerosis: report of two cases. Mov Disord 12:1092–1094CrossRefPubMedGoogle Scholar
  36. 36.
    Voller B, Földy D, Hefter H, Auff E, Schnider P (2001) Behandlung des spastischen Spitzfußes mit Botulinum Toxin Typ A bei erwachsenen Patienten. Wien Klin Wochenschr 113(Suppl 4):25–29PubMedGoogle Scholar
  37. 37.
    Ward AB, Kadies M (2002) The management of pain in spasticity. Disabil Rehabil 24:443–453CrossRefPubMedGoogle Scholar
  38. 38.
    Wissel J, Masuhr F, Schelosky L, Ebersbach G, Poewe W (1997) Quantitative assessment of botulinum toxin treatment in 43 patients with head tremor. Mov Disord 12:722–726PubMedGoogle Scholar

Copyright information

© Steinkopff-Verlag 2006

Authors and Affiliations

  1. 1.Dept. of NeurologyDeutsche Klinik für DiagnostikWiesbadenGermany

Personalised recommendations